Biopharma startup Everest Medicines closes $300m Series C round led by Hillhouse, others

Photo: Pixabay

Biopharmaceutical startup Everest Medicines on Friday announced it has raised $310 million in a Series C funding round to finance the clinical development and commercialisation of its drug candidates.

The Series C round consists of two preferred equity financing tranches, including a $260-million Series C2 round and a $50-million Series C1 round, according to a statement.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter